Aryl phosphoramidate derivatives of d4T have improved anti-HIV efficacy in tissue culture and may act by the generation of a novel intracellular metabolite

Journal of Medicinal Chemistry

Volumn 39, Issue 8, 1996, Pages 1748-1753

  McGuigan, Christopher ^a   Cahard, Dominique ^a   Sheeka, Hendrika M ^a,b   De Clercq, Erik ^a,c   Balzarini, Jan ^a,c  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINO STAVUDINE PHOSPHATE; PRODRUG; STAVUDINE; THYMIDINE KINASE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CYTOTOXICITY; DRUG SELECTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; STRUCTURE ACTIVITY RELATION;

3T3 CELLS; ANIMALS; ANTIVIRAL AGENTS; HIV; MICE; PHOSPHATES; STAVUDINE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0029975897     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm950605j     Document Type: Article

References (25)

1. Mitsuya, H.; Weinhold, K. J.; Furman, P. A.; St. Clair, M. H.; Nusinoff-Lehrman, S.; Gallo, R. C.; Bolognesi, D.; Barry, D. W.; Broder, S. (1985) 3′-Azido-3′-deoxythymidine (BWA509U): An agent that inhibits the infectivity and cytopathic effect of human T-cell lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc. Natl. Acad. Sci. U.S.A. 1985, 82, 7096-7100.
2. Mitsuya, H.; Broder, S. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotropic virus, type III/ lymphadenopathy-associated virus (HTLV III/LAV) by 2′,3′-dideoxynucleosides. Proc. Natl. Acad. Sci. U.S.A. 1986, 83, 1911-1915.
3. Balzarini, J.; Rang, G.-J.; Dalai, M.; Herdewijn, P.; De Clercq, E.; Broder, S.; Johns, D. G. The anti-HTLV-III (anti-HIV) and cytotoxic activity of 2′,3′-didehydro-2′,3′-dideoxyribonucleosides. A comparison with their parental 2′,3′-dideoxvribonucleosides. Mol. Pharmocol. 1987, 32, 162-167.
4. Herdewijn, P.; Balzarini, J.; De Clercq, E.; Pauwels, R.; Baba, M.; Broder, S.; Vanderhaeghe, H. 3′-Substituted 2′,3′-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents. J. Med. Ckem. 1987, 30, 1270-1278.
5. Balzarini, J.; Baba, M.; Pauwels, R.; Herdewijn, P.; De Clercq, E. Anti-retrovirus activity of 3′-fluoro- and 3′-azido-substituted pyrimidine 2′,3′-dideoxynucleoside analogues. Biochem. Pharmacol. 1988, 37, 2847-2856.
6. Furman, P. A.; Fyfe, J. A.; St. Clair, M. H.; Weinhold, K.; Rideout, J. L.; Freeman, G. A.; Nusinoff Lehrman, S.; Bolognesi, D, P.; Broder, S.; Mitsuya, H.; Barry, D. W. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc. Natl. Acad. Sci. U.S.A 1986, 83, 8333-8337.
7. Balzarini, J.; Herdewijn, P.; De Clercq, E. Differential patterns of intracellular metabolism of 2′,3′-didehydro-2′,3′-dideoxythy-midine and 3′-azido-2′,3′-dideoxythymidine, two potent antihuman immunodeficiency virus compounds. J. Biol. Chem. 1989, 264, 6127-6133.
8. Hao, Z.; Cooney, D. A.; Hartman, N. R.; Perno, C. F.; Fridland, A.; De Vico, A. L.; Sarngadharan, M. G.; Broder, S.; Johns, D. G. Factors determining the activity of 2′,3′-dideoxynucleosides in suppressing human immunodeficiency virus in vitro. Mol. Pharmctcol. 1988, 34, 431-435.
9. Balzarini, J.; Cooney, D. A.; Dalal, M.; Kang, G.-J.; Cupp, J. E.; De Clercq, E.; Broder, S.; Johns, D. G. 2′,3′-Dideoxycytidine: regulation of its metabolism and anti-retroviral potency by natural pyrimidine nucleosides and by inhibitors of pyrimidine micleotide synthesis. Mol. Pharmacol. 1987, 32, 798-806.
10. Starnes, M. C.; Cheng, Y.-C. Cellular metabolism of 2′,3′-dideoxycytidine, a compound active against human immunodeficiency virus in vitro. J. Biol. Chem. 1987, 262, 988-991.
11. Hao, Z.; Cooney, D. A.; Farquhar, D.; Perno, C. F.; Zhang, K.; Masood, R.; Wilson, Y.; Hartman, N. R.; Balzarini, J.; Johns, D. G. Potent chain termination activity and selective inhibition of human immunodeficiency virus reverse transcriptase by 2′,3′-dideoxyuridine-5′-triphosphate. Mol. Pharmacol. 1990, 37, 157-163.
12. Johnson, M. A.; Ahluwalia, G.; Connelly, M. C.; Cooney, D. A.; Broder, S.; Johns, D. G.; Fridland, A. Metabolic pathways for the activation of the antiretroviral agent 2′,3′-dideoxyadenosine in human lymphoid cells. J. Biol. Chem. 1988, 263, 15354-15307.
13. Johnson, M. A.; Fridland, A. Phosphorylation of 2′,3′-dideoxyinosine by cytosolic 5′-nucleotidase of human lymphoid cells. Mol. Pharmacol. 1989, 36, 291-295.
14. Perno, C. F.; Yarchoan, R.; Cooney, D. A.; Hartman, N. R.; Webb, D. S. A.; Hao, Z.; Mitsuya, H.; Johns, D. G.; Broder, S. Replication of human immunodeficiency virus in monocytes. J. Exp. Med. 1989, 169, 933-951.
15. McGuigan, C.; Pathirana, R. N.; Balzarini, J.; De Clercq, E. Intracellular delivery of bioactive AZT nucleotides by aryl phosphate derivatives of AZT. J. Med. Chem. 1993, 36, 1048-1052.
16. Baba, M.; Pauwels, R.; Herdewijn, P.; De Clercq, E.; Desmyter, J.; Vandeputte, M. Both 2′,3′-dideoxythmidine and its 2′,3′-unsaturated derivative (2′,3′-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro. Biochem. Biophys. Res. Commun. 1987, 142, 128-134.
17. Mansuri, M. M.; Hitchcock, M. J. M.; Buroker, R. A.; Bregman, C. L.; Ghazzouli, I; Desiderio, J. V.; Starrett Jr, J. E.; Sterzycki, R. Z.; Martin, J. C. Comparison of in vitro biological properties and mouse toxicities of three thymidine analogs active against human immunodeficiency virus. Antimicrob. Agents Chemother. 1990, 34, 637-641.
18. Horwitz, J. P.; Chua, J.; DaRooge, M. A.; Noel, M.; Klundt, I. L. Nucleosides. IX, The formation of 2′,3′-unsaturated pyrimidine nucleosides via a novel β-elimination reaction. J. Org. Chem. 1966, 31, 205-211.
19. Mansuri, M. M.; Starrett Jr, J. E.; Ghazzouli, L; Hitchcock, M. J. M.; Sterzycki, R. Z.; Brankovan, V; Lin, T.-S.; August, E. M.; Prusoff, W. H.; Sommadossi, J.-P.; Martin, J. C. 1-(2,3-dideoxyβ-D-glycero-pent-2-enftiranosyl)thymine. A Highly potent and selective anti-HIV agent. J. Med. Chem. 1989, 32, 461-466.
20. McGuigan, C.; Pathirana, R, N.; Mahmood, N.; Devine, K. G.; Hay, A. J. Aryl phosphate derivatives of AZT retain activity against HIV1 in cell lines which are resistant to the action of AZT. Antiviral Res. 1992, 17, 311-321.
21. 31P NMR data; Grayson, M., Griffith, E. J., Ed,.; Topics in Phosphorus Chemistry, vol. 5; Wiley: New York, 1969.
22. McGuigan, C.; Davies, M.; Pathirana, R. N.; Mahmood, N.; Hay, A. J. Synthesis and anti-HIV activity of some novel diaryl phosphate derivatives of AZT. Antiviral Res. 1994, 24, 69-77.
23. Balzarini, J.; Karlsson, A.; Perez-Perez, M.-J.; Camarasa, M.-J.; De Clercq, E. Knoeking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus. Virology 1993, 196, 576-585.
24. Balzarini, J.; Karlsson, A; Perno, C.-F ; Cahard, D.; Naesens, L.; De Clercq, E.; McGuigan, C. Dual mechanism of action of masked alaninyl d4TMP derivatives. Manuscript submitted for publication.
25. Popovic, M.; Sarngadharan M. G,; Read, E.; Gallo, R. C. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 1984, 224, 497-500.